Stryków, May 07, 2015 – Sandoz, the generic Division of Novartis is announcing today the opening of the Sandoz Packaging Centre in Stryków – a project valued at 171 million PLN. It is one of the largest investment projects in the Polish pharmaceutical sector completed in recent years. Thanks to the expansion of the existing plant in Stryków, 90 new jobs have been created to date, soon to be followed by at least 40 additional ones. The opening ceremony was attended by government officials, including Deputy Prime Minister Janusz Piechociński, local politicians, members of the local government and local community.
The drug manufacturing plant in Stryków is one of the biggest Sandoz production facilities. The 5 billion tablets manufactured every year in Stryków are exported to nearly 60 countries worldwide, including Poland. Among others, the Stryków plant produces painkillers, anti-inflammatory medicines (ketoprofen), diabetes medicines (metformin, glimepiride), as well as medications for vascular hypertension (ramipril, torasemide). As part of the enlargement of the Sandoz production and logistics site in Stryków, a modern packaging and warehousing center has been added to the existing manufacturing plant.
The ribbon-cutting ceremony was led by Deputy Prime Minister Janusz Piechociński, who underlined the importance of the Sandoz investment for the development of the Polish economy, and noted that Poland plays a significant role in the worldwide pharmaceutical industry.
At the event, the Deputy Prime Minister was joined by a number of other high-ranked officials, including the Minister of Labour and Social Policy Władysław Kosiniak-Kamysz, the Deputy Minister of Health Igor Radziewicz-Winnicki, the Ambassador of Switzerland to Poland Lukas Beglinger, the Marshal of the Łódz Province Witold Stępień, the Deputy Mayor of Łódź Marek Cieślak, the Governor of the Łódz Province Jolanta Chełmińska, and the President of the Polish Information and Foreign Investment Agency Sławomir Majman.
The construction of the Sandoz Packaging Centre took nearly two years – it started in June 2013 and ended in the second quarter of 2015. Previously, the majority of the tablets produced in Stryków were transported to other Sandoz facilities. At the first stages of the construction project, eight state-of-the-art packaging lines and a fully automated warehousing system have been installed in the new building. This will enable the packaging process to be carried out directly at the manufacturing site.
Ard van der Meij, President of the Board of Sandoz Poland said: “This investment will greatly facilitate the manufacturing and packaging process, as we will be able to pack around 4 billion of manufactured tablets, without the need to send them to external packaging facilities”. The plant is expected to reach full production by the end of 2015.
As Mr van der Meij noted, “Poland plays a vital role in our company’s growth strategy. This investment will increase the capacity of the plant and, simultaneously, reduce costs. Our decision to expand the Stryków site was motivated by two key considerations: the excellent location of the site, right at the heart of Europe, and the accessibility to highly qualified personnel”.
Currently, the company’s workforce in Poland is around 1,200, out of which about 450 employees work in Stryków. The new investment will create at least 130 new jobs. The company is still looking to hire mid-level executives, managers, laboratory technicians and shop floor workers.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. In addition, Sandoz holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal. Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products – products that are scientifically more difficult to develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).